TYRX Gains FDA Clearance For Resorbable Antibacterial Device Envelope
Executive Summary
TYRX Inc. has received FDA clearance for a fully-resorbable version of its antibacterial envelope, used to prevent surgical site infections in patients who receive implantable devices such as ICDs. The resorbable device has important advantages over the previous durable envelope and could substantially boost physician adoption of the company’s technology.
You may also be interested in...
Medtronic Takes Aim At Implantable Device Infections With TYRX Buy
The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than a pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances for use of its products with cardiac implantable electronic devices and spinal cord neurostimulators.
Medtronic Takes Aim At Implantable Device Infections with TYRX Buy
The $160 million cash acquisition fits with the firm’s efforts to fashion itself into a health care services and solutions company, rather than pure device firm. TYRX makes anti-bacterial envelopes for implanted devices, and has FDA clearances with cardiac implantable electronic devices and spinal cord neurostimulators.
TYRX: Is This the Model for Drug/Device Convergence?
TYRX has a novel device - an antibiotic-impregnated envelope designed to prevent infections in CRM implants - that could create signifcant opportunities, not just for itself, but also for large CRM companies looking to differentiate their devices in a flat, crowded market. Convergence has fallen on hard times recently, but TYRX hopes to succeed where others have failed by stripping risk out of drug/device convergence.